Effect of Kollidon® SR on the release of Albuterol Sulphate from matrix tablets

Sakr, Walid F.; Alanazi, Fars K.; Sakr, Adel

doi:10.1016/j.jsps.2010.11.002

Cited by 32 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, we calculated the t 75% values for all batches, and the data showed marked enhancement of t 75% values from 3.64 to 7.93 (Table IV) indicating that the F-1 is the best formulation among the developed formulations. This finding indicates considerable release retarding potentiality of the Kollidon SR that was also reported by previous work (Sakr, Alanazi, 2011). The relationship between release rate and polymer content is shown in Figure 3.…”

Section: Resultssupporting

confidence: 87%

See 1 more Smart Citation

Development and evaluation of sustained release losartan potassium matrix tablet using kollidon SR as release retardant

Sarwar

Hossain

2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The present study was undertaken to develop sustained release (SR) matrix tablets of losartan potassium, an angiotensin-II antagonist for the treatment of hypertension. The tablets were prepared by direct compression method, along with Kollidon SR as release retardant polymer. The amount of losartan potassium remains fixed (100 mg) for all the three formulations whereas the amounts of Kollidon SR were 250 mg, 225 mg, and 200 mg for F-1, F-2, and F-3 respectively. The evaluation involves three stages: the micromeritic properties evaluation of granules, physical property studies of tablets, and in-vitro release kinetics studies. The USP apparatus type II was selected to perform the dissolution test, and the dissolution medium was 900 mL phosphate buffer pH 6.8. The test was carried out at 75 rpm, and the temperature was maintained at 37 o C ± 0.5 o C. The release kinetics was analyzed using several kinetics models. Higher polymeric content in the matrix decreased the release rate of drug. At lower polymeric level, the rate and extent of drug release were enhanced. All the formulations followed Higuchi release kinetics where the Regression co-efficient (R 2 ) values are 0.958, 0.944, and 0.920 for F-1, F-2, and F-3 respectively, and they exhibited diffusion dominated drug release. Statistically significant (P<0.05) differences were found among the drug release profile from different level of polymeric matrices. The release mechanism changed from non-fickian (n=0.489 for F-1) to fickian (n=0.439 and 0.429 for F-2, and F-3 respectively) as a function of decreasing the polymer concentration. The Mean Dissolution Time (MDT) values were increased with the increase in polymer concentration. Uniterms:Losartan potassium/sustained release/development. Losartan potassium/sustained release/ evaluation. Tablets/direct compression. Kollidon SR./use/release retardant.O presente estudo foi realizado para desenvolver (SR) matriz de comprimidos de liberação sustentada de losartana, um antagonista da angiotensina II, para o tratamento da hipertensão arterial. Os comprimidos foram preparados pelo método de compressão direta com Kollidon SR como polímero de liberação lenta. A quantidade de losartana potássica permanece fixa (100 mg) para todas as três formulações enquanto que as quantidades de Kollidon SR foram de 250 mg, 225 mg e 200 mg para F-1, F-2 e F-3, respectivamente. A avaliação envolve três etapas-propriedades micromeríticas dos grânulos, estudo das propriedades físicas dos comprimidos e estudos de cinética de liberação in vitro.. Selecionoou-se o aparelho USP tipo II para realizar o teste de dissolução em meio com 900 mL de tampão fosfato pH 6,8 . O teste foi realizado em 75 rpm e a temperatura foi mantida a 37 o C ± 0.5 o C. Analisou-se a cinética de liberação utilizando-se vários modelos cinéticos. Conteúdo mais alto de polímero na matriz reduziu a taxa de liberação do fármaco. Em níveis mais baixos de polímero, a taxa e a extensão de liberação do fármaco foram aumentados. Todas as formulações seguiram a cinética de libera...

show abstract

Section: Resultssupporting

confidence: 87%

“…The drug content (n=3) of the formulated tablet among different batches ranged from 99.7±1.2% to (Sakr, Alanazi, 2011). This is one of the most common reasons for choosing the Kollidon SR as release retardant polymer as compared to all others hydrophobic polymer.…”

Section: Resultsmentioning

confidence: 99%

Development and evaluation of sustained release losartan potassium matrix tablet using kollidon SR as release retardant

Sarwar

Hossain

2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…After filtration (Spanatan, 0.2 lm, Whatman, USA), the amount of buprenorphine HCl released into the medium was measured by HPLC and was expressed as a percentage of the initial buprenorphine HCl loading in the polymer solutions. Data obtained from release measurements was fitted to zero order, first-order, Higuchi's, and Korsmeyer-Peppas equations (Sakr et al, 2011).…”

Section: Kinetics Of In Vitro Drug Releasementioning

confidence: 99%

Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride

Koocheki

Madaeni

Niroomandi³

2011

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

To control the minimum effective dose, and reduce the number and quantity of administered potent drugs are unique features of advanced drug delivery in situ forming gel formulation. The efficacy, consistency, and increasing the application of existing injection therapies can be enhanced through optimization of controlled released systems by using FDA approved biodegradable PLGA (poly-d,l-lactide-co-glycolide) polymer. The purpose of this study was to develop different in situ forming implant (ISFI) formulations of buprenorphine hydrochloride for post treatment of drug addicts, acute and chronic pains. The drug releases from different ISFIs membranes with and without Tween 80 were compared over a period of time. Kinetic equation followed the Korsmeyer-Peppas model, as the plots showed high linearity. The influence of this additive on polymer properties was investigated using differential scanning calorimetry (DSC), and the membranes structure was studied by X-ray diffractometry (XRD) and scanning electron microscope (SEM). Data revealed that Tween 80 modified the drug release pattern using diffusion mechanism and decreased the glass transition temperature (T g) significantly. The degree of crystallinity was decreased after phase inversion which helps the dissolution of drug from membrane. The porosity of modified membranes was in accordance with release profiles. These findings suggest four different in situ forming implant formulations which can release various dose of the buprenorphine hydrochloride in a prolonged time. Also this surfactant can be an attractive additive for modifying the release rate of drugs from PLGA-based membrane drug delivery systems.

show abstract

“…Binder selection for a particular system is quite often empirical and dependent on the skills and experience of the formulator. Type and concentration of binder system are the main variables controlling the desired product quality such as granule friability, tablet friability, hardness, disintegration time, and the drug dissolution rate (Sakr et al, 2011).…”

Section: Binder Solutions As Granulating Agentsmentioning

confidence: 99%

Upgrading wet granulation monitoring from hand squeeze test to mixing torque rheometry

Sakr

Ibrahim

Alanazi

et al. 2012

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

With over 50 years of research in granulation technology, however more research is required to elucidate this widely applicable technology. Wetting phenomena could influence redistribution of individual ingredients within a granule according their solubility and also could affect the drying processes. Binder selection for a particular system is quite often empirical and dependent on the skills and experience of the formulator. Hand squeeze test was and still the main way for determination of wet granulation end point, but it is subjected to individual variation. It depends mainly on operator experience, so it is not possible to be validated. Literature reveals a variety of advanced monitoring techniques following up different wet massing stages. Torque measurement has been proved to be the most reliable control method as its tight relation to mass resistance. Many reports showed successful applications of mixing torque rheometer (MTR) for monitoring the wet massing procedure and scale up in addition to some preformulation applications. MTR as a new approach allows formulators to select a liquid addition range where the granule growth behavior is more predictable.

show abstract

Effect of Kollidon® SR on the release of Albuterol Sulphate from matrix tablets

Cited by 32 publications

References 27 publications

Development and evaluation of sustained release losartan potassium matrix tablet using kollidon SR as release retardant

Development and evaluation of sustained release losartan potassium matrix tablet using kollidon SR as release retardant

Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride

Upgrading wet granulation monitoring from hand squeeze test to mixing torque rheometry

Contact Info

Product

Resources

About